Nav: Home

New guidelines push for better controlled experiments with synthetic nucleic acids

April 04, 2019

New Rochelle, NY, April 4, 2019--Researchers have proposed new guidelines to overcome current problems facing scientists developing synthetic nucleic acids - such as antisense oligonucleotides and double-stranded RNAs - as drugs and research tools. The guidelines, which promote a common set of standards for judging experiments and more efficient use of resources, are published in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers. Click here to read the full-text, open access article for free on the Nucleic Acid Therapeutics website.

In the article entitled "Guidelines for Experiments Using Antisense Oligonucleotides and Double-Stranded RNAs" coauthors Keith Gagnon, School of Medicine, Southern Illinois University (Carbondale) and David Corey, UT Southwestern Medical Center at Dallas, TX state that current experimental designs are too often inadequate, leading to misleading interpretation of data and findings that are unsupportable and a waste of resources.

The authors provide practical advice for performing experiments with synthetic nucleic acids, including long noncoding RNAs (lncRNAs) and microRNAs (miRNAs) and present minimum standards for published research. They focus on topics including experimental design, measuring gene expression, measuring cell uptake, selecting controls for cell culture experiments and animal studies, and special cases.

"The issue of proper controls for oligonucleotide studies has been extensively discussed by the board of the Oligonucleotide Therapeutic Society. This thoughtful set of guidelines has now been endorsed by both the board of the Oligonucleotide Therapeutic Society and the editorial board of Nucleic Acid Therapeutics. This paper reinforces our continuing commitment to improving experimental design and we encourage submission of further commentaries that share this goal," says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.
-end-
Research reported in this publication was supported by the National Institutes of Health under Award NumberR35GM118103. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About the Journal

Nucleic Acid Therapeutics is an authoritative peer-reviewed journal published bimonthly in print and online that focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. The Journal is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center and Annemieke Aartsma-Rus, PhD, Leiden University Medical Center, and Executive Editor Graham C. Parker, PhD. Nucleic Acid Therapeutics is the official journal of the Oligonucleotide Therapeutics Society (https://www.oligotherapeutics.org/). Complete tables of content and a sample issue may be viewed on the Nucleic Acid Therapeutics website.

About the Society

The Oligonucleotide Therapeutics Society is an open, non-profit forum to foster academia- and industry-based research and development of oligonucleotide therapeutics. The society brings together the expertise from different angles of oligonucleotide research to create synergies and to bring the field of oligonucleotides to its full therapeutic potential.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy, Assay and Drug Development Technologies, Applied In Vitro Toxicology, and DNA and Cell Biology. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Mary Ann Liebert, Inc./Genetic Engineering News

Related Nucleic Acid Therapeutics Articles:

A novel method to precisely deliver therapeutics inside the body
A new way to deliver therapeutic proteins inside the body uses an acoustically sensitive carrier to encapsulate the proteins and ultrasound to image and guide the package to the exact location required, according to Penn State researchers.
New findings shed light on selective therapeutics for IDH1-mutated glioma
Findings of a new study led by Prof. XU Guowang from the Dalian Institute of Chemical Physics (DICP) of the Chinese Academy of Sciences and Prof.
Paving the way for new peptide-based therapeutics with novel method of phage display
Chemists at Texas A&M University are taking a p[h]age from bacteria's playbook in order to beat viruses at their own game and develop new drugs to fight cancer and a host of other human diseases in the process.
New method accelerates development of protein therapeutics
Northwestern Engineering researchers have developed a quick, cell-free system to create biosynthetic pathways to build and study sugar structures.
New insights into the structure and function of Cdc34, a target for cancer therapeutics
Medical University of South Carolina researchers report in Nature Communications they have obtained 3D structural snapshots of Cdc34 in action.
'Green Revolution' in RNAi tools and therapeutics
A team from Nanjing University in China reported that the small silencing RNA sequences against HBsAg generated in edible lettuce (Lactuca sativa L.) can specifically bind and inhibit gene expression in p21-HBsAg knock-in transgenic mice and improve liver injury at a relatively low level when compared to synthetic siRNAs.
Best practices of nucleic acid amplification tests for the diagnosis of clostridioides (clostridium)
A new review looks at the challenges of testing for Clostridioides (Clostridium) difficile infection (CDI) and recommendations for newer diagnostic tests.
Texas A&M research team develops bioinks to print therapeutics in 3D
A team of researchers at Texas A&M University has developed an innovative way to print therapeutics in 3D for regenerative medicine.
New guidelines push for better controlled experiments with synthetic nucleic acids
Researchers have proposed new guidelines to overcome current problems facing scientists developing synthetic nucleic acids -- such as antisense oligonucleotides and double-stranded RNAs -- as drugs and research tools.
Yumanity Therapeutics announces publication of paper in Cell Reports
Yumanity Therapeutics, a company focused on discovering transformative therapies to treat neurodegenerative diseases, today announced the publication of study results describing a potential new target for therapeutic intervention in Parkinson's disease and other related disorders.
More Nucleic Acid Therapeutics News and Nucleic Acid Therapeutics Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Processing The Pandemic
Between the pandemic and America's reckoning with racism and police brutality, many of us are anxious, angry, and depressed. This hour, TED Fellow and writer Laurel Braitman helps us process it all.
Now Playing: Science for the People

#568 Poker Face Psychology
Anyone who's seen pop culture depictions of poker might think statistics and math is the only way to get ahead. But no, there's psychology too. Author Maria Konnikova took her Ph.D. in psychology to the poker table, and turned out to be good. So good, she went pro in poker, and learned all about her own biases on the way. We're talking about her new book "The Biggest Bluff: How I Learned to Pay Attention, Master Myself, and Win".
Now Playing: Radiolab

Invisible Allies
As scientists have been scrambling to find new and better ways to treat covid-19, they've come across some unexpected allies. Invisible and primordial, these protectors have been with us all along. And they just might help us to better weather this viral storm. To kick things off, we travel through time from a homeless shelter to a military hospital, pondering the pandemic-fighting power of the sun. And then, we dive deep into the periodic table to look at how a simple element might actually be a microbe's biggest foe. This episode was reported by Simon Adler and Molly Webster, and produced by Annie McEwen and Pat Walters. Support Radiolab today at Radiolab.org/donate.